Clorox (NYSE:CLX) PT Lowered to $136.00

Clorox (NYSE:CLX) had its price objective lowered by stock analysts at Barclays from $148.00 to $136.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “underweight” rating on the stock. Barclays‘s price target would suggest a potential downside of 5.80% from the stock’s current price.

Several other equities analysts have also recently commented on the company. Jefferies Financial Group raised Clorox from an “underperform” rating to a “hold” rating and set a $145.00 price target for the company in a report on Tuesday, March 26th. Morgan Stanley restated an “equal weight” rating and set a $160.00 target price on shares of Clorox in a research report on Tuesday, March 26th. DA Davidson reissued a “neutral” rating and issued a $162.00 target price on shares of Clorox in a research note on Monday, February 5th. Bank of America upgraded shares of Clorox from an “underperform” rating to a “neutral” rating and upped their target price for the company from $120.00 to $150.00 in a research report on Friday, December 15th. Finally, JPMorgan Chase & Co. raised their target price on Clorox from $145.00 to $152.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Four analysts have rated the stock with a sell rating and twelve have given a hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $149.13.

Clorox Trading Up 0.2 %

Shares of CLX traded up $0.35 during midday trading on Wednesday, hitting $144.37. The stock had a trading volume of 1,000,819 shares, compared to its average volume of 1,226,831. Clorox has a fifty-two week low of $114.68 and a fifty-two week high of $178.21. The business has a 50-day simple moving average of $151.56 and a two-hundred day simple moving average of $141.24. The company has a current ratio of 0.89, a quick ratio of 0.57 and a debt-to-equity ratio of 11.37. The firm has a market cap of $17.92 billion, a P/E ratio of 229.13, a price-to-earnings-growth ratio of 2.26 and a beta of 0.43.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Thursday, February 1st. The company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $1.08 by $1.08. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.80 billion. Clorox had a return on equity of 319.41% and a net margin of 1.09%. Clorox’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.98 earnings per share. As a group, equities analysts forecast that Clorox will post 5.51 EPS for the current year.

Institutional Investors Weigh In On Clorox

Large investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC raised its holdings in shares of Clorox by 0.5% in the fourth quarter. CIBC Private Wealth Group LLC now owns 13,900 shares of the company’s stock valued at $1,982,000 after purchasing an additional 66 shares during the last quarter. GHP Investment Advisors Inc. raised its holdings in shares of Clorox by 1.3% in the fourth quarter. GHP Investment Advisors Inc. now owns 5,132 shares of the company’s stock valued at $720,000 after purchasing an additional 66 shares during the last quarter. Toroso Investments LLC raised its holdings in shares of Clorox by 1.3% in the first quarter. Toroso Investments LLC now owns 5,266 shares of the company’s stock valued at $833,000 after purchasing an additional 68 shares during the last quarter. First National Bank of Mount Dora Trust Investment Services raised its holdings in shares of Clorox by 3.2% in the fourth quarter. First National Bank of Mount Dora Trust Investment Services now owns 2,257 shares of the company’s stock valued at $322,000 after purchasing an additional 71 shares during the last quarter. Finally, Modera Wealth Management LLC raised its holdings in shares of Clorox by 1.4% in the third quarter. Modera Wealth Management LLC now owns 5,130 shares of the company’s stock valued at $672,000 after purchasing an additional 71 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.